calcineurin inhibitor
Jump to navigation
Jump to search
Indications
- chronic maintenance immunosuppression after organ transplantation
Adverse effects
- hypertension (treated with thiazide diuretics)
- oral calcineurin inhibitors cyclosporine & tacrolimus are associated with excess risk for non-melamoma skin cancers & lymphomas
- topical calcineurin inhibitors tacrolimus & pimecrolimus are not[3]
- topical calcineurin inhibitors are associated with increased risk of lymphomas (RR=1.9)[4]
Drug interactions
- drugs that increase calcineurin inhibitor levels
- antimicrobial agents
- capsofungin
- azole
- macrolides
- chloroquine
- antiviral protease inhibitor
- ofloxacin
- calcium channel blockers
- diltiazem
- verapamil
- amlodipine (less so)
- felodipine (less so)
- nicardipine
- benzodiazepines
- alprozolam
- diazepam
- danazol
- grapefruit juice
- allopurinol
- setralins
- antimicrobial agents
- drugs that decrease calcineurin inhibitor levels
Mechanism of action
- agents that inhibit calcineurin
More general terms
More specific terms
- calcineurin-binding protein cabin-1; calcineurin inhibitor; CAIN (CABIN1, KIAA0330)
- cyclosporin A (Sandimmune, Neoral [CsA])
- pimecrolimus (Elidel)
- tacrolimus; FK506; fujimycin (Prograf, Advagraf, Envarsus XR)
- voclosporin (Lupkynistm)
Additional terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
- ↑ Moes AD, Hesselink DA, Zietse R et al Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014 Jun;15(9):1243-51. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25141899
- ↑ 3.0 3.1 Asgari MM et al. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 2020 Aug 12; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32785626 https://jamanetwork.com/journals/jamadermatology/fullarticle/2768937
- ↑ 4.0 4.1 Lam M, Zhu JW, Tadrous M et al Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma. A Systematic Review and Meta-analysis. JAMA Dermatol. Published online March 31, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33787818 https://jamanetwork.com/journals/jamadermatology/fullarticle/2778024